

1 ***Plasmodium falciparum* malaria drives epigenetic reprogramming of human monocytes**
2 **toward a regulatory phenotype**

3 ¹Rajan Guha*, ²Anna Mathioudaki, ⁵Safiatou Doumbo, ⁵Didier Doumtabe, ¹Jeff Skinner, ³Gunjan
4 Arora, ⁴Shafiuddin Siddiqui, ¹Shanping Li, ⁵Kassoum Kayentao, ⁵Aissata Ongoiba, ²Judith Zaugg,
5 ⁵Boubacar Traore, ¹Peter D. Crompton*

6

7 ¹Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National
8 Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland,
9 United States

10 ²Structural and Computational Biology Unit, The European Molecular Biology Laboratory,
11 Heidelberg, Germany

12 ³Section of Infectious Diseases, Department of Internal Medicine, Yale University School of
13 Medicine, New Haven, Connecticut, United States

14 ⁴Laboratory of Genome Integrity, Center for Cancer Research, National Cancer Institute,
15 National Institutes of Health, Bethesda, Maryland, United States

16 ⁵Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases,
17 International Center of Excellence in Research, University of Sciences, Technique and
18 Technology of Bamako, Bamako, Mali

19 *Correspondence: Rajan Guha (rajan.guha@nih.gov), Peter D. Crompton

20 (pcrompton@niaid.nih.gov)

21

22 Running Title: Monocyte tolerance in malaria

23 Keywords: *Plasmodium falciparum* malaria, monocytes, tolerance, inflammation, human
24 studies, epigenetics

25 **Abstract**

26 In malaria-naïve children and adults, *Plasmodium falciparum*-infected red blood cells (*Pf*-iRBCs)
27 trigger fever and other symptoms of systemic inflammation. However, in endemic areas where
28 individuals experience repeated *Pf* infections over many years, the risk of *Pf*-iRBC-triggered
29 inflammatory symptoms decreases with cumulative *Pf* exposure. The molecular mechanisms
30 underlying these clinical observations remain unclear. Age-stratified analyses of monocytes
31 collected from uninfected, asymptomatic Malian individuals before the malaria season revealed
32 an inverse relationship between age and *Pf*-iRBC-inducible inflammatory cytokine (IL-1 β , IL-6
33 and TNF) production, whereas Malian infants and malaria-naïve U.S. adults produced similarly
34 high levels of inflammatory cytokines. Accordingly, monocytes of Malian adults produced more
35 IL-10 and expressed higher levels of the regulatory molecules CD163, CD206, Arginase-1 and
36 TGM2. These observations were recapitulated in an *in vitro* system of monocyte to macrophage
37 differentiation wherein macrophages re-exposed to *Pf*-iRBCs exhibited attenuated
38 inflammatory cytokine responses and a corresponding decrease in the epigenetic marker of
39 active gene transcription, H3K4me3, at inflammatory cytokine gene loci. Together these data
40 indicate that *Pf* induces epigenetic reprogramming of monocytes/macrophages toward a
41 regulatory phenotype that attenuates inflammatory responses during subsequent *Pf* exposure.
42 These findings also suggest that past malaria exposure could mitigate monocyte-associated
43 immunopathology induced by other pathogens such as SARS-CoV-2.

44 **Author Summary**

45 The malaria parasite is mosquito-transmitted and causes fever and other inflammatory
46 symptoms while circulating in the bloodstream. However, in regions of high malaria
47 transmission the parasite is less likely to cause fever as children age and enter adulthood, even
48 though adults commonly have malaria parasites in their blood. Monocytes are cells of the
49 innate immune system that secrete molecules that cause fever and inflammation when
50 encountering microorganisms like malaria. Although inflammation is critical to initiating normal
51 immune responses, too much inflammation can harm infected individuals. In Mali, we
52 conducted a study of a malaria-exposed population from infants to adults and found that
53 participants' monocytes produced less inflammation as age increases, whereas monocytes of
54 Malian infants and U.S. adults, who had never been exposed to malaria, both produced high
55 levels of inflammatory molecules. Accordingly, monocytes exposed to malaria in the laboratory
56 became less inflammatory when re-exposed to malaria again later, and these monocytes
57 'turned down' their inflammatory genes. This study helps us understand how people become
58 immune to inflammatory symptoms of malaria and may also help explain why people in
59 malaria-endemic areas appear to be less susceptible to the harmful effects of inflammation
60 caused by other pathogens such as SARS-CoV-2.

61 Introduction

62 *Plasmodium falciparum* infection in non-immune individuals can result in severe, life-
63 threatening malaria when *P. falciparum*-infected red blood cells (*Pf*-iRBCs) trigger systemic
64 inflammation [1],[2] and sequester in blood vessels of vital organs [3]. Conversely, in areas of
65 intense malaria transmission, *P. falciparum*-infected individuals are commonly asymptomatic
66 [4], even when parasitemia exceeds that which predictably induces fever and other
67 inflammatory symptoms in non-immune individuals. Non-sterilizing, clinical immunity to blood-
68 stage malaria can be acquired with repeated infections over years and is associated with the
69 acquisition of *P. falciparum*-specific humoral and cellular adaptive immune responses [5, 6]. The
70 relatively inefficient acquisition of adaptive immunity that protects from malaria has been
71 ascribed to the extensive genetic diversity of *P. falciparum* parasites [7], the clonal variation in
72 proteins the parasite exports to the erythrocyte surface [8], and dysregulation of B and T cell
73 responses [9, 10].

74

75 Less is known about the impact of cumulative *P. falciparum* exposure on cells of the innate
76 immune system, such as monocytes and macrophages, and how this may relate to the
77 acquisition of clinical immunity. During *Plasmodium* blood-stage infection, circulating blood
78 monocytes and tissue macrophages perform crucial effector functions that contribute to host
79 defense against malaria including cytokine production, phagocytosis of infected erythrocytes,
80 and antigen presentation [11]. However, excessive production of pro-inflammatory cytokines
81 such IL-1 β , IL-6 and TNF by monocytes/macrophages can result in systemic inflammation that
82 causes fever and other disease manifestations of malaria [11, 12].

83 Recent studies have shown that various immune perturbations can epigenetically and
84 metabolically reprogram monocytes/macrophages, such that after cells return to a non-
85 activated state, their response to subsequent challenges is altered [13]. Depending on the
86 nature of the initial immune perturbation, the subsequent response of
87 monocytes/macrophages may be diminished (tolerance) or enhanced (trained immunity)
88 relative to the primary response [13]. It has been shown that immune training of monocytes
89 can be generated at the level of myeloid progenitors in the bone marrow [14], which could
90 explain how monocytes, which survive in circulation for only 1-7 days [15], could exhibit a
91 'memory' phenotype for 3-12 months after the primary stimulus [13].

92

93 Therefore, we hypothesized that *P. falciparum* exposure is associated with functional changes
94 in circulating monocytes that persist in the absence of ongoing malaria exposure when
95 monocytes have returned to a non-activated steady state. More specifically, given the long-
96 standing clinical observation that individuals become 'tolerant' to the inflammatory effects of
97 blood-stage malaria [16], we hypothesized that an inverse relationship exists between age (a
98 surrogate for cumulative malaria exposure in endemic areas) and *Pf*-iRBC-inducible
99 inflammatory cytokine production from monocytes at their non-activated steady state.

100

101 To test this hypothesis, we analyzed the phenotype and function of monocytes obtained from
102 an age-stratified cohort study in Mali that spans infancy to adulthood. Monocytes were
103 collected cross-sectionally from asymptomatic, uninfected study volunteers at the end of the 6-
104 month dry season, which is a period of negligible *P. falciparum* transmission. In addition, we

105 adapted an in vitro system of monocyte to macrophage differentiation to directly investigate
106 the impact of *P. falciparum* blood-stage parasites on monocytes/macrophages at the molecular
107 level.

108

109 **Results**

110 **Malaria exposure associates with reduced production of *Pf*-inducible inflammatory cytokines** 111 **and increased production of IL-10 from monocytes**

112 To analyze the relationship between malaria exposure and monocyte function we isolated
113 monocytes from subjects enrolled in an age-stratified cohort in Mali and also from healthy
114 malaria-naïve U.S. adults as controls. A detailed description of the Kalifabougou cohort has
115 been published [17]. Malian subjects ranged from 4-6-month-old infants born during the six-
116 month dry season, when malaria transmission is negligible [18], to adults exposed to a lifetime
117 of repeated *P. falciparum* infections. All Malian subjects in this cross-sectional analysis were
118 negative for *P. falciparum* infection by PCR at the time of blood collection, which occurred just
119 before the 6-month malaria season. To simulate re-exposure to *P. falciparum* blood-stage
120 parasites in vitro, isolated monocytes were co-cultured with *P. falciparum*-infected red blood
121 cells (*Pf*-iRBCs) at a ratio of 1:30 (monocytes:*Pf*-iRBCs) for 24 hours [19]. Secreted cytokines
122 were measured in supernatants by bead-based multiplex arrays. Among the Malian subjects we
123 observed an inverse relationship between age and the production of the inflammatory
124 cytokines TNF, IL-1 β and IL-6, whereas Malian infants and malaria-naïve U.S. adults produced
125 similarly high levels of inflammatory cytokines (Figure 1 A-C). In contrast, production of the
126 anti-inflammatory cytokine IL-10 increased with age among Malian subjects, whereas Malian

127 infants and malaria-naïve U.S. adults produced similarly low levels of IL-10 (Figure 1D). Taken
128 together, these data suggest that cumulative malaria exposure, or exposure to other factors
129 associated with malaria transmission, skews monocytes toward a regulatory phenotype
130 characterized by decreased *P. falciparum*-inducible production of inflammatory, pyrogenic
131 cytokines and increased production of the anti-inflammatory cytokine IL-10, consistent with the
132 epidemiological observation that febrile malaria risk decreases with cumulative malaria
133 exposure in this cohort [17], and in areas of intense malaria transmission more generally [20].

134

135 **Monocytes of malaria-exposed adults skew toward a regulatory profile phenotypically and**
136 **transcriptionally**

137 Next, we examined the molecular basis of malaria-associated skewing of monocytes toward a
138 regulatory phenotype by comparing the phenotypic and transcriptional profiles of monocytes
139 collected before the malaria season from Malian children and adults, as well as malaria-naïve
140 U.S. adults. PBMCs of Malian children (aged 4-6 years; n=9) and adults (n=9), as well as U.S.
141 adults (n=7) were analyzed *ex vivo* by flow cytometry for surface expression of the myeloid cell
142 markers CD14, CD16, CD86, CD163, CD206 and HLA-DR [21] gated on live monocytes.
143 Visualization of the flow cytometry data by distributed stochastic neighbor embedding (t-SNE)
144 analysis [22] revealed that monocytes of Malian adults expressed higher levels of the regulatory
145 or alternatively activated (M2) monocytes/macrophage markers CD163 and CD206 compared
146 to Malian children and U.S. adults (Figure 2A); and CD163 and CD206 expression was largely
147 confined to the CD14⁺ and CD14⁺CD16⁺ monocyte clusters (Figure 2B). Consistent with the t-

148 SNE visualization, MFI values of CD163 and CD206 were significantly higher on monocytes of
149 Malian adults compared to Malian children and U.S. adults (Figure 2C and D).
150 M2 regulatory monocytes/macrophages are known to produce high levels of arginase 1 [23].
151 Therefore we further tested the hypothesis that cumulative malaria exposure is associated with
152 skewing of monocytes towards an M2 regulatory phenotype by stimulating PBMCs of Malian
153 children (aged 4-6 years; n=9) and adults (n=9), as well as U.S. adults (n=9) with *Pf*-iRBCs for 18
154 hours and quantifying intracellular arginase-1 in monocytes by flow cytometry. Visualization of
155 the flow cytometry data by t-SNE analysis showed that monocytes of Malian adults produced
156 higher levels of arginase 1 in response to *Pf*-iRBC stimulation compared to Malian children and
157 U.S. adults (Figure 2E). Consistent with the t-SNE plots, MFI values of arginase 1 were
158 significantly higher within monocytes of Malian adults compared to Malian children and U.S.
159 adults (Figure 2F).

160

161 To further investigate the molecular basis of malaria-associated skewing of monocytes toward
162 an M2 regulatory type, we conducted whole genome RNA-seq analysis of monocytes isolated
163 from Malian children and adults. RNA-seq was performed on unstimulated monocytes (n=4
164 from each age group) as well as monocytes that had been stimulated with *Pf*-iRBCs for 24 hours
165 (n=8 from each age group) to simulate re-exposure to *P. falciparum* blood-stage parasites.
166 Monocytes were stimulated with *Pf*-iRBCs at a ratio of 1:5 (monocytes:*Pf*-iRBCs) to reduce *P.*
167 *falciparum* nucleic acid during RNA sequencing. Principal components analysis of the RNA-seq
168 data showed segregation of transcription profiles based on age—an effect that became more
169 pronounced following stimulation with *Pf*-iRBCs (Figure 3A). Here we focused on differential

170 gene expression between monocytes of children versus adults following *Pf*-iRBC stimulation.
171 Consistent with the analysis of secreted cytokines (Figure 1), Malian children had significantly
172 higher expression of the genes encoding TNF [log₂ fold change (FC) 1.8, Benjamini-Hochberg
173 (BH) adjusted p value = 0.0001] and IL6 (FC 2.3, BH p = 0.007) compared to Malian adults
174 (Figure 3B and C; Supplemental Table). In addition, the expression of *TLR5*, *TLR7*, *CXCL9*,
175 *CXCL10*, *NLRP1*, *NLRP3*, *FCGR3A*, *PTX3* and various HLA molecules was significantly upregulated
176 in children relative to adults (Figures 3B-E; Supplemental Table for FC and adjusted p values).
177 Consistent with the blunted pro-inflammatory cytokine responses that we observed from
178 monocytes of Malian adults in response to *Pf*-iRBC stimulation (Figure 1), expression of *NFKB1*,
179 a positive regulator of inflammation, was downregulated (FC -3.8, BH p = 4.6 E-26) in
180 monocytes of adults relative to children (Figure 3C; Supplemental Table), while expression of
181 the multifunctional enzyme transglutaminase-2 (*TGM2*), a known marker of the M2 regulatory
182 phenotype, was significantly higher (FC 7.5, BH p = 1.7 E-79) in monocytes of adults versus
183 children (Figures 3B and D; Supplemental Table). Accordingly, expression of the chemokines
184 *CCL22* (FC 5.0, BH p = 9.2 E-21) and *CCL24* (FC 9.6, BH p = 3.8 E-21) were upregulated in adult
185 monocytes, consistent with the chemokine repertoire of M2 regulatory
186 monocytes/macrophages [24].
187
188 Together these data indicate that monocytes of Malian adults are skewed toward a regulatory
189 phenotype, whereas monocytes of Malian children more closely resemble those of malaria-
190 naïve U.S. adults, suggesting that cumulative malaria exposure, or other factors associated with

191 malaria transmission, and not age *per se*, drives functional changes in monocytes that persist in
192 uninfected individuals.

193

194 **Pre-exposure of monocytes to *P. falciparum* blunts subsequent inflammatory responses to *P.***
195 ***falciparum* and LPS**

196 The Malian adults in this study whose monocytes skew toward a regulatory phenotype have
197 been exposed to a lifetime of repeated *P. falciparum* infections, but whether *P. falciparum per*
198 *se* can drive this phenotype remains unclear. To more directly test this hypothesis, and to
199 further dissect the molecular mechanisms underlying our ex vivo observations, we adapted an
200 in vitro model of monocyte to macrophage differentiation [25] to incorporate exposure to *P.*
201 *falciparum* blood-stage parasites (Figure 4). Briefly, elutriated monocytes from healthy U.S.
202 adults were incubated for 24 hours with medium alone, uninfected red blood cells (RBC) or *Pf-*
203 *iRBC*. At 24 hours, supernatants and cells were collected from some replicate wells for cytokine
204 analysis, while monocytes in other replicate wells were washed and incubated for 3 additional
205 days in human serum and medium to allow monocytes to differentiate into macrophages (Mf).
206 On day 5, the three populations of macrophages were either harvested for ChIP and cytokine
207 gene expression analysis or re-stimulated with *Pf-iRBCs* or lipopolysaccharide for 24 hours prior
208 to measuring cytokines in supernatants. Of note, on day 5, cell frequency and viability did not
209 differ significantly between macrophages in medium alone (Mf) or following co-culture with
210 RBCs (RBC-Mf) or *Pf-iRBCs* (*Pf-iRBC-Mf*) (Supplementary Figure 2). Also of note, titration
211 experiments determined that a monocyte:*Pf-iRBC* ratio of 1:15 optimally balanced cytokine
212 production and monocyte viability in this model (Supplementary Figure 1).

213

214 As expected, monocytes of U.S. adults (n=3) co-cultured for 24 hours with *Pf*-iRBCs upregulated
215 the expression of genes encoding several pro-inflammatory cytokines including TNF, IL-6 and IL-
216 1 β (Figure 5A), which was confirmed at the protein level in an independent experiment of U.S.
217 adults (n=9) by cytokine analysis of supernatants (Figure 5D-F). On day 5, after monocytes had
218 matured into macrophages, pro-inflammatory cytokine gene expression by *Pf*-iRBC-Mfs
219 decreased relative to the 24-hour timepoint but remained higher than pro-inflammatory
220 cytokine gene expression in the Mf and RBC-Mf controls (Figure 5B), consistent with the
221 removal of *Pf*-iRBC by washing at the 24-hour timepoint. On day 5, Mf, RBC-Mf and *Pf*-iRBC-Mf
222 were co-cultured with *Pf*-iRBC lysate. After 24 hours, gene expression analysis showed
223 upregulation of several pro-inflammatory cytokines in Mf and RBC-Mf relative to the 5-day
224 timepoint that was not apparent in *Pf*-iRBC-Mf (Figure 5C). This pattern was confirmed at the
225 protein level for TNF, IL-6 and IL-1 β in an independent experiment of U.S. adults (n=9) by
226 cytokine analysis of supernatants (Figure 5G-I). Plots of Δ Ct values (mean \pm SE of the 3 subjects
227 in Figure 5A-C) for TNF and IL-6 at the three timepoints (Figure 5J and K) further illustrates how
228 pre-exposure of monocytes to *P. falciparum* blunts the subsequent inflammatory response of
229 newly differentiated macrophages upon restimulation with *P. falciparum*. We observed a
230 similar dampening of TNF, IL-6 and IL-1 β responses to LPS in *Pf*-iRBC-Mf (Figure 5L-N).

231

232 ***P. falciparum* exposure induces epigenetic changes in monocytes consistent with regulation**
233 **of inflammation**

234 Epigenetic modifications in monocytes/macrophages underpin the immunological imprinting of
235 tolerance or trained immunity following exposure to LPS or β -glucan, respectively [25]. Here we
236 hypothesized that *P. falciparum* induces epigenetic modifications in the regulatory regions of
237 pro-inflammatory genes such that inflammatory responses are dampened upon re-exposure to
238 *P. falciparum* (i.e. tolerance). To test this hypothesis, we performed Chromatin
239 Immunoprecipitation (ChIP) on monocytes/macrophages collected at each of the 3 timepoints
240 shown in Figure 4 using an antibody specific for H3K4me3, an epigenetic modification
241 of Histone H3 enriched at active promoters that positively correlates with transcription [26].

242

243 After 24-hours, monocytes stimulated with *Pf*-iRBC were enriched for the active H3K4me3
244 histone mark at the TNF and IL-6 promoter regions relative to monocytes incubated with RBCs
245 or medium alone (Figure 6A, D), consistent with cytokine data at the same timepoint (Figure
246 5D-F). On day 5, after maturation of monocytes into macrophages (Mf), the active H3K4me3
247 histone mark remained enriched at the TNF and IL-6 promoter regions of cells that had been
248 stimulated with *Pf*-iRBC (*Pf*-iRBC-Mf) relative to macrophages initially incubated with RBCs
249 (RBC-Mf) or medium alone (Mf) (Figure 6B, E). After the three cell populations (Mf, RBC-Mf and
250 *Pf*-iRBC-Mf) were stimulated with *Pf*-iRBC for 24 hours, the active H3K4me3 histone mark
251 became enriched in the TNF and IL-6 promoter regions of the Mf and RBC-Mf populations,
252 whereas the active H3K4me3 histone mark decreased in the TNF and IL-6 promoter regions in
253 the *Pf*-iRBC-Mf population (Figure 6C, F). Plots of the H3K4me3 histone mark at the TNF and IL-
254 6 promoter regions at all three timepoints further illustrate how pre-exposure to *P. falciparum*
255 diminishes H3K4me3 histone mark enrichment of newly differentiated macrophages upon

256 restimulation with *P. falciparum* (Figure 6G and H)—an epigenetic pattern of TNF and IL-6
257 regulation consistent with the pattern of TNF and IL-6 expression in the same model (Figure 5J
258 and K).

259

260

261 **Discussion**

262 In areas of intense malaria transmission the risk of febrile malaria decreases with age as
263 individuals are exposed to repeated *P. falciparum* infections over many years [17]. The
264 relatively slow development of clinical immunity to malaria is associated with the gradual
265 acquisition of *P. falciparum*-specific adaptive immune responses [27]. Here we sought to
266 understand the impact of *P. falciparum* exposure on the phenotype and function of innate
267 immune cells, namely, the monocyte/macrophage lineage—an important source of fever-
268 inducing pro-inflammatory cytokines during blood-stage malaria infection [11].

269

270 In the Mali cohort we observed an inverse relationship between age and *Pf*-iRBC-inducible
271 production of the inflammatory cytokines IL-1 β , IL-6 and TNF from monocytes; whereas
272 monocytes of Malian infants born during the dry season (negligible *P. falciparum* transmission)
273 and malaria-naïve U.S. adults produced similarly high levels of inflammatory cytokines,
274 indicating that age alone is not responsible for the functional changes in monocytes observed in
275 the Mali cohort, but rather malaria exposure itself and/or other factors associated with malaria
276 transmission. In addition, monocytes of Malian adults produced higher levels of the anti-
277 inflammatory cytokine IL-10 in response to *Pf*-iRBC stimulation. Consistent with these

278 functional data, monocytes of Malian adults expressed higher levels of the regulatory
279 molecules CD163, CD206, Arginase-1 and TGM2 [28-32].

280

281 Importantly, the monocytes analyzed in this study were collected from uninfected,
282 asymptomatic individuals at the end of the 6-month dry season when the immune system is in
283 a relatively non-activated state. Since monocytes survive in circulation for only 1-7 days [15],
284 we postulate that the skewing of circulating monocytes toward a tolerant phenotype with
285 increasing age reflects the ‘reprogramming’ of bone marrow progenitor cells by past malaria
286 exposure and/or other immune perturbations associated with malaria transmission. This
287 hypothesis is consistent with recent studies in mice showing that BCG or β -glucan can
288 epigenetically and metabolically reprogram myeloid progenitors in the bone marrow [33, 34]—
289 a mechanism that may be particularly relevant to malaria as the bone marrow is a major site of
290 growth and sexual development for *Plasmodium* parasites [35]. Alternatively, a recent study
291 using the rodent malaria model by Nahrendorf *et al.* found that epigenetic reprogramming of
292 monocytes in tolerized hosts occurs within the spleen [36].

293

294 We previously found in longitudinal analyses of Malian children that *Pf*-iRBC-inducible
295 production of IL-1 β and IL-6 by monocytes was lower 7 days after treatment of febrile malaria
296 relative to that induced at the pre-infection baseline before the six-month malaria season [19].
297 However, the skewing of monocytes toward a tolerant phenotype in children after febrile
298 malaria seems to depend on ongoing *P. falciparum* exposure, as children’s monocytes generally
299 appear to return to a ‘non-tolerant’ steady-state baseline after the subsequent 6-month dry

300 season [19]. However, a study in the same cohort found that children who are resistant to
301 febrile malaria begin the malaria season with evidence of tolerized monocytes that upregulate
302 p53, which is associated with attenuation of *Plasmodium*-induced inflammation [37].
303 Interestingly, a study conducted in a region of Uganda where *P. falciparum* transmission occurs
304 year-round found that older children had a dampened pro-inflammatory serum cytokine
305 response during acute malaria compared to younger children [38], consistent with the notion
306 that ongoing exposure may be required to maintain a tolerant state in most children.

307
308 That innate immune ‘memory’ may be relatively short-lived after a single immune perturbation
309 is consistent with other studies that show the trained immunity phenotype persists for at least
310 3 months and up to 1 year [13]. Therefore, it seems plausible that with each 6-month malaria
311 season, the homeostatic setpoint of monocytes gradually shifts toward a tolerant phenotype
312 such that adults maintain a tolerant phenotype even through the 6-month dry season. This is
313 consistent with whole blood transcriptome analysis of Malian adults who exhibited a blunted
314 inflammatory response during *P. falciparum* infection relative to Dutch adults who were
315 experimentally infected with *P. falciparum* for the first time [39].

316
317 To more directly assess the impact *P. falciparum* blood-stage parasites on
318 monocytes/macrophages and to gain insight into potential molecular mechanisms of
319 *Plasmodium*-induced tolerance, we employed an *in vitro* system of monocyte to macrophage
320 differentiation and *P. falciparum* co-culture [25, 40]. With this model we found at both the
321 mRNA and protein levels that macrophages derived from monocytes previously exposed to *Pf*-

322 iRBCs had an attenuated inflammatory cytokine response upon re-exposure to *Pf*-iRBCs or
323 exposure to the TLR4 agonist LPS. This corresponded to a decrease in the epigenetic marker of
324 active gene transcription, H3K4me3, at inflammatory cytokine gene loci. These findings are
325 consistent with the hypothesis that malaria contributes directly to the reprogramming of
326 monocytes/macrophages toward a tolerant phenotype.

327 Given the non-specific nature of monocyte tolerance, the findings of this study may have
328 implications for vaccine responsiveness and the clinical course of non-malaria infections in
329 malaria-exposed populations, even when individuals are uninfected and asymptomatic. For
330 example, studies of the PfSPZ malaria vaccine in Mali and Tanzania reported an inverse
331 relationship between cumulative *P. falciparum* exposure or transmission intensity and vaccine-
332 specific antibody responses [41, 42]. Given that monocytes can help initiate vaccine-specific
333 adaptive immunity through cytokine production, and to a lesser extent antigen processing and
334 presentation, it is plausible that tolerized monocytes play a role in vaccine hypo-responsiveness
335 in malaria-endemic areas. It is also conceivable that tolerized monocytes/macrophages could
336 modify the clinical manifestations of non-malaria infections, particularly those linked to
337 monocyte/macrophage-associated pathological inflammation. For example, severe acute
338 respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus
339 disease 2019 (COVID-19) pandemic, has been associated with excessive inflammation, including
340 high levels of circulating IL-6 and TNF, that is thought to be a major cause of disease severity
341 and death in patients with COVID-19 [43]. In much of Africa to date, the COVID-19 pandemic
342 has not been as severe as predicted [44]. Although many environmental, genetic, sociocultural
343 and institutional factors could contribute to lower COVID-19 morbidity and mortality in Africa

344 compared to other regions [45], we speculate that COVID-19 severity in Africa may be mitigated
345 by pre-existing differences in the immune system, including tolerized monocytes that produce
346 lower levels of pro-inflammatory cytokines when activated.

347

348 In contrast to our findings here, recent studies have reported that malaria induces a state of
349 hyper-responsiveness [40, 46, 47] that is functionally similar to the trained immunity induced
350 by BCG vaccination [13]. For example, Schrum et al. found that initial stimulation with Pf-iRBCs
351 induced human adherent PBMCs to hyper-respond to subsequent stimulation with the TLR2
352 agonist Pam3CSK4. These findings may differ from the present study for several reasons. In
353 contrast to purified monocytes used in the present study, Schrum et al. performed *in vitro*
354 studies with adherent PBMCs, which may contain cells other than monocyte/macrophages. In
355 addition, our *in vitro* studies used a higher cell to Pf-iRBC ratio (1:15 vs. 1:0.5) that more closely
356 approximates *in vivo* parasitemia during febrile malaria. Finally, we restimulated
357 monocytes/macrophages with Pf-iRBCs rather than TLR agonists alone.

358

359 Taken together, our findings offer mechanistic insight into the long-standing clinical observation
360 that individuals exposed to intense malaria transmission can tolerate malaria parasites in their
361 blood at levels that would predictably produce fever in previously unexposed individuals [16].
362 In future studies it will be of interest to determine the generalizability of these findings in other
363 malaria-exposed populations and to assess the extent to which variation in transmission
364 intensity influence monocyte phenotype and function. In addition, it will be of interest to track

365 *ex vivo* monocyte epigenetic profiles within individuals over time and with repeated infections
366 to better understand the quality and kinetics of malaria-induced tolerance.

367

368

369

370 **Materials and Methods**

371 **Study subjects**

372 The field study was conducted in the rural village of Kalifabougou, Mali where intense *P.*
373 *falciparum* transmission occurs from June through December each year. The cohort study has
374 been described in detail elsewhere [17]. Briefly, 695 healthy children and adults aged 3 months
375 to 25 years were enrolled in an ongoing cohort study in May 2011. Exclusion criteria at
376 enrollment included a hemoglobin level <7 g/dL, axillary temperature $\geq 37.5^{\circ}\text{C}$, acute systemic
377 illness, underlying chronic disease, or use of antimalarial or immunosuppressive medications in
378 the past 30 days. The present study focused on children aged 6-months to 8 years and adults.
379 For this study venous blood samples were collected from study subjects at their healthy
380 uninfected baseline before the malaria season. The ethics committee of the Faculty of
381 Medicine, Pharmacy and Dentistry at the University of Sciences, Techniques and Technology of
382 Bamako, and the Institutional Review Board of NIAID NIH approved the study (ClinicalTrials.gov
383 NCT01322581). Written, informed consent was obtained from the parents or guardians of
384 participating children or from adult participants.

385

386 **PBMC processing**

387 Blood samples (8 ml) were drawn by venipuncture into sodium citrate-containing cell
388 preparation tubes (BD, Vacutainer CPT Tubes) and transported 20 km to the laboratory where
389 PBMCs were isolated and frozen within three hours according to the manufacturer's
390 instructions. PBMCs were frozen in human AB serum (Sigma) containing 10% dimethyl sulfoxide
391 (DMSO; Sigma-Aldrich, St. Louis, MO), kept at -80°C for 24 hours, and then stored in liquid
392 nitrogen.

393 **Isolation of monocytes**

394 PBMCs and elutriated monocytes were obtained from healthy U.S. volunteers by counterflow
395 centrifugal elutriation at the National Institutes of Health (NIH) Blood Bank under Institutional
396 Review Board approved protocols of both the National Institute of Allergy and Infectious
397 Diseases and the Department of Transfusion Medicine. Elutriated monocytes were further
398 purified with a monocyte isolation kit (Stem Cell technologies) to minimize donor-to-donor
399 variability in contaminating cell populations. Monocyte purity was routinely >98% as assessed
400 by flow cytometry. Similarly, monocytes were isolated from PBMCs of Malian donors by a
401 negative selection monocyte isolation kit (Stem Cell Technologies) without depleting CD16 such
402 that monocytes were isolated 'untouched'. Non-monocyte/macrophage cells were directly
403 depleted with a cocktail of biotin-conjugated antibodies followed by magnetic removal of
404 labeled cells.

405

406 **Preparation of *P. falciparum*-infected red blood cell lysate for in vitro stimulation**

407 3D7 *P. falciparum* parasites were maintained in fresh human ORh⁺ erythrocytes at 3%
408 hematocrit in RPMI 1640 medium (KD Medical) supplemented with 10% heat-inactivated ORh⁺

409 human serum (Interstate Blood Bank, Memphis, Tennessee), 7.4% Sodium Bicarbonate (GIBCO,
410 Invitrogen) and 25 mg/ml of gentamycin (GIBCO, invitrogen), at 37°C in the presence of a gas
411 mixture containing 5% O₂, 5% CO₂ and 90% N₂. Parasite cultures were confirmed to be free of
412 mycoplasma and acholeplasma using an ELISA-based Mycoplasma Detection Kit (Roche) which
413 contains polyclonal antibodies specific for *M. arginini*, *M. hyorhinis*, *A. laidlawii* and *M. orale*. *P.*
414 *falciparum*-infected red blood cells (Pf-iRBCs) were enriched for knobs using Zeptogel (contains
415 gelatin) sedimentation. Pf-iRBCs were enriched at the schizont stage with percoll-sorbitol
416 gradient and centrifugation, washed, and resuspended in complete medium in the absence of
417 human serum or Pf-iRBCs schizonts were isolated in RPMI 1640 medium supplemented with
418 0.25% Albumax (GIBCO, Invitrogen) and 7.4% Sodium Bicarbonate (GIBCO, Invitrogen) using
419 magnetic columns (LD MACS Separation Columns, Miltenyi Biotec). Control preparations of
420 uninfected red blood cells (RBCs) from the same blood donor were obtained and tested in all
421 experiments. Lysates of Pf-iRBCs and RBCs were obtained by three freeze-thaw cycles using
422 liquid nitrogen and a 37°C water bath.

423

424 **In vitro stimulation of PBMCs and monocytes with *P. falciparum*-infected red blood cell lysate**
425 Monocytes or PBMCs were cultured with RBCs or Pf-iRBCs. Cells were cultured in complete
426 RPMI (RPMI 1640 plus 10% human AB serum, 1% penicillin/streptomycin), at 37°C in a 5% CO₂
427 atmosphere. PBMCs were stimulated with RBC or Pf-iRBC lysate at a ratio of 3 RBCs or 3 Pf-
428 iRBCs per PBMC, whereas monocytes were stimulated at a ratio of 5-30 RBCs or 5-30 Pf-iRBCs
429 per monocyte. For *in vitro* experiments with elutriated monocytes, cells were first allowed to

430 adhere in monocyte attachment medium (Promocell) for 1.5 hr before culturing as described
431 above.

432

433 **Flow cytometry**

434 PBMCs were washed in PBS with 4% heat-inactivated FCS, incubated for 15 min on ice with a
435 live-dead dye in PBS, washed, and then surface stained with lymphocyte lineage dump-APC
436 (CD3, CD19, CD56, CD20), CD14-BUV805, CD206-BV421, CD163-FITC, CD16-BUV395, HLA-DR-
437 APC-R700 and CD86-BV650. For intracellular staining, following surface staining cells were fixed
438 and permeabilized using a Foxp3 staining kit (e-biosciences). Cells were then stained with
439 Arginase1-PE-Cy7 in permeabilization buffer. After washing, cells were resuspended in 4% heat-
440 inactivated FCS containing FACS buffer and data were acquired by a Symphony Flow Cytometer
441 (BD Biosciences). Flow cytometry and t-SNE analyses were performed with FlowJo software
442 (FlowJo10.5.3). For t-SNE analysis, down sampling was done on live monocytes which were
443 devoid of aggregates and dead cells, followed by concatenating the samples according to
444 biological replicates and sample group. Finally, the default t-SNE algorithm was run with 1000
445 iterations, perplexity 30 and a learning rate of 200.

446

447 **Cytokine measurements in supernatants**

448 Supernatants were thawed and immediately analyzed with Bio-plex human cytokine assays
449 (Bio-Rad Laboratories, Inc.) following the manufacturer's instructions. The following cytokines
450 were measured: IL-1 β , IL-6, IL-10 and TNF. Briefly, 50 μ L of supernatant was incubated with
451 anti-cytokine antibody-coupled magnetic beads for 30 min at room temperature with shaking

452 at 300 RPM in the dark. Between each step the complexes were washed three times in wash
453 buffer using a vacuum manifold. The beads were then incubated with a biotinylated detector
454 antibody for 30 min before incubation with streptavidin-phycoerythrin for 30 minutes. Finally,
455 the complexes were resuspended in 125 mL of detection buffer and 100 beads were counted
456 with a Luminex 200 device (Bio-Rad Laboratories, Inc.). Final concentrations were calculated
457 from the mean fluorescence intensity and expressed in pg/mL using standard curves with
458 known concentrations of each cytokine.

459

460 **RNA isolation, RNA-Seq and cytokine gene expression array**

461 Cells were kept in RNAProtect buffer (Qiagen) at -80°C until RNA was isolated. RNA was isolated
462 using the RNeasy kit according to the manufacturer's instructions. The quality and quantity of
463 isolated RNA was determined with the Agilent Bioanalyzer. Only RNA with RIN values greater
464 than 7 were used for analyses. cDNA was prepared from 10 ng of total RNA using the Ovation®
465 RNA-Seq System V2 (Tecan) according to manufacturer's instructions. This method employs
466 both poly-T and random primers so that both poly-adenylated and non-poly-adenylated RNA is
467 included. The cDNA product was end-repaired using the NEBNext End Repair Module (New
468 England Biolabs). RNA-Seq libraries were prepared using 1 µg of end-repaired cDNA using the
469 TruSeq Stranded RNA Kit (Illumina), however due to the method of amplification the libraries
470 were not stranded. Unique dual-indexed barcode adapters were applied to each library.
471 Libraries were pooled in an equimolar ratio for sequencing. The pooled libraries were
472 sequenced on one lane of an S4 flow cell on a NovaSeq 6000 using version 1 chemistry to
473 achieve a minimum of 49 million 150 base pair reads. The data was processed using RTA

474 version 3.4.4 and BWA-0.7.12. For the RNA-seq analysis, quality control and adapter trimming
475 were performed using FASTQC and cutadapt, respectively (Martin, 2013). Then, the reads were
476 aligned to the hg19 reference genome using STAR aligner (Dobin et al., 2013). Reads were
477 counted using featureCounts (Liao, Smyth, & Shi, 2014). For the identification of differentially
478 expressed genes among the different groups, we used DESeq2 with the design formula “~
479 condition” (Love, Huber, & Anders, 2014). Benjamini-Hochberg (BH) correction was performed
480 with an adjusted p-value threshold set to 0.01. For the gene expression array, we used
481 TaqMan™ Array, Human Cytokine Network, fast 96-well plate, and real time PCR was
482 performed from isolated cDNA according to the manufacturer’s instructions. cDNA was isolated
483 from RNA using the Superscript-VILO cDNA synthesis kit followed by Real Time RTPCR using
484 TaqMan™ Fast Advanced Master Mix using the Quant Studio™ 6 instrument.

485

486 **Cell culture**

487 For ChIP analysis and Taqman RNA Array analysis, 10×10^6 elutriated and purified monocytes
488 were plated on 100 mm dishes. Monocytes were pre-incubated with cell culture medium
489 (RPMI), Pf-iRBCs or RBCs for 24 hours in a total volume of 10 mL. After wash-out, cells were
490 cultured in RPMI supplemented with 10% human pooled AB serum containing homeostatic
491 levels of M-CSF that induces macrophage differentiation. Cells were collected at 24 hours and
492 on day 5 were counted prior to chromatin immunoprecipitation. After wash-out, cells were
493 cultured in RPMI supplemented with 10% human pooled AB serum. For cytokines production,
494 2.5×10^4 to 5×10^4 purified or elutriated monocytes were plated in a 96 well flat bottom plate.
495 Monocytes were pre-incubated as above for 24 hours in a total volume of 100-200 μ L. After a

496 wash-out, cells were cultured in RPMI supplemented with 10% human pooled serum and
497 supernatants were collected for analysis.

498

499 **ChIP analysis**

500 Briefly, cells were fixed in 1% formaldehyde for 10 min and quenched with glycine. Chromatin
501 was sonicated from these cells using a Bioruptor Pico (Diagenode) for four cycles of 10× (30 s
502 ON, 30s OFF) on the HIGH setting. Chromatin precipitation was performed using rabbit anti-
503 human H3K4me3 IgG Ab (Active Motif) as described previously [48]. DNA was then quantified
504 using qPCR with the following primer pairs: IL-6, FW 5'-AGCTCTATCTCCCCTCCAGG-3', RV 5'-
505 ACACCCCTCCCTCACACAG-3'; TNF, FW 5'-CAGGCAGGTTCTTCTCTCT-3', RV 5'-
506 GCTTTCAGTGCTCATGGTGT-3'[40]. For all ChIP experiments, qPCR values were normalized as
507 percent recovery of the input DNA.

508

509 **Statistical analysis**

510 Most continuous data were compared using the unpaired Mann-Whitney test or paired
511 Wilcoxon sign rank test, as appropriate. Bonferroni adjustments were applied to correct for
512 multiple comparisons where needed. One-way or two-way ANOVA with Tukey post hoc tests
513 were used to compare continuous variables in situations where data was assumed to be normal
514 or where the two-way experimental design precluded a nonparametric test. All statistical tests
515 are specified in the figure legends. Statistical significances were defined using 2-tailed p-values
516 or adjusted p-values of 0.05 or less. Most statistical tests were computed using GraphPad Prism
517 version 8 (<http://www.graphpad.com/scientific-software/prism/>). Some heatmaps, principal

518 components analysis (PCA) plots and t-SNE plots were produced using R 3.6.1 or FlowJo
519 (version 10.5)

520

521 **Geo Accession ID:** GSE151116

522

523 **Acknowledgments**

524 We thank the residents of Kalifabougou, Mali, for participating in this study. We also thank Dr.
525 Alice Young and other members of the National Human Genome Research Institute for the RNA
526 sequencing. This work was supported by the Division of Intramural Research of the National
527 Institute of Allergy and Infectious Diseases, National Institutes of Health.

528

529 **References**

- 530 1. Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, et al. Serum levels of the proinflammatory
531 cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in
532 Malian children with severe *Plasmodium falciparum* malaria and matched uncomplicated malaria or
533 healthy controls. *Infect Immun*. 2004;72(10):5630-7. Epub 2004/09/24. doi: 10.1128/IAI.72.10.5630-
534 5637.2004. PubMed PMID: 15385460; PubMed Central PMCID: PMC517593.
535
- 536 2. Walther M, Woodruff J, Edele F, Jeffries D, Tongren JE, King E, et al. Innate immune responses to
537 human malaria: heterogeneous cytokine responses to blood-stage *Plasmodium falciparum* correlate
538 with parasitological and clinical outcomes. *J Immunol*. 2006;177(8):5736-45. Epub 2006/10/04. doi:
539 10.4049/jimmunol.177.8.5736. PubMed PMID: 17015763.
540
- 541 3. Smith JD, Rowe JA, Higgins MK, Lavstsen T. Malaria's deadly grip: cytoadhesion of *Plasmodium*
542 *falciparum*-infected erythrocytes. *Cell Microbiol*. 2013;15(12):1976-83. Epub 2013/08/21. doi:
543 10.1111/cmi.12183. PubMed PMID: 23957661; PubMed Central PMCID: PMC3836831.
544
- 545 4. Portugal S, Tran TM, Ongoiba A, Bathily A, Li S, Doumbo S, et al. Treatment of Chronic Asymptomatic
546 *Plasmodium falciparum* Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection. *Clin*
547 *Infect Dis*. 2017;64(5):645-53. Epub 2017/04/01. doi: 10.1093/cid/ciw849. PubMed PMID: 28362910;
548 PubMed Central PMCID: PMC6075513.
549

- 550 5.Kurup SP, Butler NS, Harty JT. T cell-mediated immunity to malaria. *Nat Rev Immunol.* 2019;19(7):457-
551 71. Epub 2019/04/04. doi: 10.1038/s41577-019-0158-z. PubMed PMID: 30940932; PubMed Central
552 PMCID: PMC6599480.
- 553
- 554 6.Perez-Mazliah D, Ndungu FM, Aye R, Langhorne J. B-cell memory in malaria: Myths and realities.
555 *Immunol Rev.* 2020;293(1):57-69. Epub 2019/11/17. doi: 10.1111/imr.12822. PubMed PMID: 31733075;
556 PubMed Central PMCID: PMC6972598.
- 557
- 558 7.Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and
559 overcoming 'vaccine resistant malaria'. *Parasite Immunol.* 2009;31(9):560-73. Epub 2009/08/21. doi:
560 PIM1138 [pii] 10.1111/j.1365-3024.2009.01138.x. PubMed PMID: 19691559.
- 561 8.Scherf A, Lopez-Rubio JJ, Riviere L. Antigenic variation in *Plasmodium falciparum*. *Annu Rev Microbiol.*
562 2008;62:445-70. Epub 2008/09/13. doi: 10.1146/annurev.micro.61.080706.093134. PubMed PMID:
563 18785843.
- 564
- 565 9.Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory B cells in human chronic
566 infectious diseases: An interim report. *Cell Immunol.* 2017;321:18-25. Epub 2017/07/25. doi:
567 10.1016/j.cellimm.2017.07.003. PubMed PMID: 28735813; PubMed Central PMCID: PMC65732066.
- 568 10.Kumar R, Loughland JR, Ng SS, Boyle MJ, Engwerda CR. The regulation of CD4(+) T cells during
569 malaria. *Immunol Rev.* 2020;293(1):70-87. Epub 2019/11/02. doi: 10.1111/imr.12804. PubMed PMID:
570 31674682.
- 571
- 572 11.Dobbs KR, Crabtree JN, Dent AE. Innate immunity to malaria-The role of monocytes. *Immunol Rev.*
573 2020;293(1):8-24. Epub 2019/12/17. doi: 10.1111/imr.12830. PubMed PMID: 31840836; PubMed
574 Central PMCID: PMC6986449.
- 575
- 576 12.Stanisis DI, Cutts J, Eriksson E, Fowkes FJ, Rosanas-Urgell A, Siba P, et al. gammadelta T cells and
577 CD14+ monocytes are predominant cellular sources of cytokines and chemokines associated with severe
578 malaria. *J Infect Dis.* 2014;210(2):295-305. Epub 2014/02/14. doi: 10.1093/infdis/jiu083. PubMed PMID:
579 24523513.
- 580
- 581 13.Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained
582 immunity and its role in health and disease. *Nat Rev Immunol.* 2020;20(6):375-88. Epub 2020/03/07.
583 doi: 10.1038/s41577-020-0285-6. PubMed PMID: 32132681; PubMed Central PMCID: PMC67186935.
- 584
- 585 14.Chavakis T, Mitroulis I, Hajishengallis G. Hematopoietic progenitor cells as integrative hubs for
586 adaptation to and fine-tuning of inflammation. *Nat Immunol.* 2019;20(7):802-11. Epub 2019/06/20. doi:
587 10.1038/s41590-019-0402-5. PubMed PMID: 31213716; PubMed Central PMCID: PMC6709414.
- 588
- 589 15.Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate and lifespan of human
590 monocyte subsets in steady state and systemic inflammation. *J Exp Med.* 2017;214(7):1913-23. Epub
591 2017/06/14. doi: 10.1084/jem.20170355. PubMed PMID: 28606987; PubMed Central PMCID:
592 PMC65502436.
- 593
- 594 16.Boutlis CS, Yeo TW, Anstey NM. Malaria tolerance--for whom the cell tolls? *Trends Parasitol.*
595 2006;22(8):371-7. Epub 2006/06/21. doi: S1471-4922(06)00131-0 [pii]10.1016/j.pt.2006.06.002.
596 PubMed PMID: 16784889.

- 597 17. Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, Dia S, et al. An intensive longitudinal cohort study
598 of Malian children and adults reveals no evidence of acquired immunity to *Plasmodium falciparum*
599 infection. *Clin Infect Dis*. 2013;57(1):40-7. Epub 2013/03/15. doi: 10.1093/cid/cit174. PubMed PMID:
600 23487390; PubMed Central PMCID: PMCPMC3669526.
601
- 602 18. Andrade CM, Fleckenstein H, Thomson-Luque R, Doumbo S, Lima NF, Anderson C, et al. Increased
603 circulation time of *Plasmodium falciparum* underlies persistent asymptomatic infection in the dry
604 season. *Nat Med*. 2020. Epub 2020/10/28. doi: 10.1038/s41591-020-1084-0. PubMed PMID: 33106664.
605
- 606 19. Portugal S, Moebius J, Skinner J, Doumbo S, Doumtabe D, Kone Y, et al. Exposure-dependent control
607 of malaria-induced inflammation in children. *PLoS Pathog*. 2014;10(4):e1004079. Epub 2014/04/20. doi:
608 10.1371/journal.ppat.1004079. PubMed PMID: 24743880; PubMed Central PMCID: PMCPMC3990727.
609
- 610 20. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers.
611 *Nat Immunol*. 2008;9(7):725-32. Epub 2008/06/20. doi: ni.f.205 [pii] 10.1038/ni.f.205. PubMed PMID:
612 18563083.
- 613 21. Kapellos TS, Bonaguro L, Gemund I, Reusch N, Saglam A, Hinkley ER, et al. Human Monocyte Subsets
614 and Phenotypes in Major Chronic Inflammatory Diseases. *Front Immunol*. 2019;10:2035. Epub
615 2019/09/24. doi: 10.3389/fimmu.2019.02035. PubMed PMID: 31543877; PubMed Central PMCID:
616 PMCPMC6728754.
617
- 618 22. van der Maaten L, Hinton G. Visualizing Data using t-SNE. *J Mach Learn Res*. 2008;9:2579–605.
619
- 620 23. Shrivastava R, Shukla N. Attributes of alternatively activated (M2) macrophages. *Life Sci*.
621 2019;224:222-31. Epub 2019/04/01. doi: 10.1016/j.lfs.2019.03.062. PubMed PMID: 30928403.
622
- 623 24. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse
624 forms of macrophage activation and polarization. *Trends Immunol*. 2004;25(12):677-86. Epub
625 2004/11/09. doi: 10.1016/j.it.2004.09.015. PubMed PMID: 15530839.
626
- 627 25. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajani refah A, Matarese F, et al. Epigenetic programming
628 of monocyte-to-macrophage differentiation and trained innate immunity. *Science*.
629 2014;345(6204):1251086. Epub 2014/09/27. doi: 10.1126/science.1251086. PubMed PMID: 25258085;
630 PubMed Central PMCID: PMCPMC4242194.
631
- 632 26. Fanucchi S, Mhlanga MM. Lnc-ing Trained Immunity to Chromatin Architecture. *Front Cell Dev Biol*.
633 2019;7:2. Epub 2019/02/09. doi: 10.3389/fcell.2019.00002. PubMed PMID: 30733945; PubMed Central
634 PMCID: PMCPMC6353842.
635
- 636 27. Crompton PD, Moebius J, Portugal S, Waisberg M, Hart G, Garver LS, et al. Malaria immunity in man
637 and mosquito: insights into unsolved mysteries of a deadly infectious disease. *Annu Rev Immunol*.
638 2014;32:157-87. doi: 10.1146/annurev-immunol-032713-120220. PubMed PMID: 24655294; PubMed
639 Central PMCID: PMCPMC4075043.
640
- 641 28. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects.
642 *Antioxid Redox Signal*. 2013;18(17):2352-63. Epub 2012/08/21. doi: 10.1089/ars.2012.4834. PubMed
643 PMID: 22900885; PubMed Central PMCID: PMCPMC3638564.

- 644
645 29.Gordon S, Pluddemann A, Martinez Estrada F. Macrophage heterogeneity in tissues: phenotypic
646 diversity and functions. *Immunol Rev.* 2014;262(1):36-55. Epub 2014/10/17. doi: 10.1111/imr.12223.
647 PubMed PMID: 25319326; PubMed Central PMCID: PMC4231239.
648
649 30.Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol.*
650 2008;8(12):958-69. Epub 2008/11/26. doi: 10.1038/nri2448. PubMed PMID: 19029990; PubMed Central
651 PMCID: PMC2724991.
652
653 31.Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest.*
654 2012;122(3):787-95. Epub 2012/03/02. doi: 10.1172/JCI59643. PubMed PMID: 22378047; PubMed
655 Central PMCID: PMC3287223.
656
657 32.Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, et al. Genetic programs expressed in
658 resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences.
659 *Blood.* 2013;121(9):e57-69. Epub 2013/01/08. doi: 10.1182/blood-2012-06-436212. PubMed PMID:
660 23293084.
661
662 33.Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, et al. Modulation of Myelopoiesis
663 Progenitors Is an Integral Component of Trained Immunity. *Cell.* 2018;172(1-2):147-61 e12. Epub
664 2018/01/13. doi: 10.1016/j.cell.2017.11.034. PubMed PMID: 29328910; PubMed Central PMCID:
665 PMC5766828.
666
667 34.Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonca LE, Pacis A, et al. BCG Educates Hematopoietic Stem
668 Cells to Generate Protective Innate Immunity against Tuberculosis. *Cell.* 2018;172(1-2):176-90 e19. Epub
669 2018/01/13. doi: 10.1016/j.cell.2017.12.031. PubMed PMID: 29328912.
670
671 35.Venugopal K, Hentzschel F, Valkiunas G, Marti M. Plasmodium asexual growth and sexual
672 development in the haematopoietic niche of the host. *Nat Rev Microbiol.* 2020;18(3):177-89. Epub
673 2020/01/11. doi: 10.1038/s41579-019-0306-2. PubMed PMID: 31919479; PubMed Central PMCID:
674 PMC7223625.
675
676 36.Nahrendorf W, Ivens A, Spence PJ. Inducible mechanisms of disease tolerance provide an alternative
677 strategy of acquired immunity to malaria. *bioRxiv.* 2020. doi:
678 <https://doi.org/10.1101/2020.10.01.322180>.
679
680 37.Tran TM, Guha R, Portugal S, Skinner J, Ongoiba A, Bhardwaj J, et al. A Molecular Signature in Blood
681 Reveals a Role for p53 in Regulating Malaria-Induced Inflammation. *Immunity.* 2019;51(4):750-65 e10.
682 Epub 2019/09/08. doi: 10.1016/j.immuni.2019.08.009. PubMed PMID: 31492649; PubMed Central
683 PMCID: PMC7163400.
684
685 38.Farrington L, Vance H, Rek J, Prah M, Jagannathan P, Katureebe A, et al. Both inflammatory and
686 regulatory cytokine responses to malaria are blunted with increasing age in highly exposed children.
687 *Malar J.* 2017;16(1):499. Epub 2017/12/30. doi: 10.1186/s12936-017-2148-6. PubMed PMID: 29284469;
688 PubMed Central PMCID: PMC5747142.
689
690 39.Tran TM, Jones MB, Ongoiba A, Bijker EM, Schats R, Venepally P, et al. Transcriptomic evidence for
691 modulation of host inflammatory responses during febrile Plasmodium falciparum malaria. *Sci Rep.*

- 692 2016;6:31291. Epub 2016/08/11. doi: 10.1038/srep31291. PubMed PMID: 27506615; PubMed Central
693 PMCID: PMCPMC4978957.
- 694
- 695 40.Schrum JE, Crabtree JN, Dobbs KR, Kiritsy MC, Reed GW, Gazzinelli RT, et al. Cutting Edge:
696 Plasmodium falciparum Induces Trained Innate Immunity. *J Immunol.* 2018;200(4):1243-8. Epub
697 2018/01/14. doi: 10.4049/jimmunol.1701010. PubMed PMID: 29330325; PubMed Central PMCID:
698 PMCPMC5927587.
- 699
- 700 41.Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et al. Safety and Differential
701 Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ
702 Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. *Am J Trop Med Hyg.*
703 2019;100(6):1433-44. Epub 2019/04/18. doi: 10.4269/ajtmh.18-0835. PubMed PMID: 30994090;
704 PubMed Central PMCID: PMCPMC6553883.
- 705
- 706 42.Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety,
707 Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium
708 falciparum Sporozoite Vaccine in Tanzanian Adults. *Am J Trop Med Hyg.* 2018;99(2):338-49. Epub
709 2018/06/27. doi: 10.4269/ajtmh.17-1014. PubMed PMID: 29943719; PubMed Central PMCID:
710 PMCPMC6090339.
- 711 43.Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes
712 and macrophages. *Nat Rev Immunol.* 2020;20(6):355-62. Epub 2020/05/08. doi: 10.1038/s41577-020-
713 0331-4. PubMed PMID: 32376901; PubMed Central PMCID: PMCPMC7201395.
- 714
- 715 44.Mbow M, Lell B, Jochems SP, Cisse B, Mboup S, Dewals BG, et al. COVID-19 in Africa: Dampening the
716 storm? *Science.* 2020;369(6504):624-6. Epub 2020/08/09. doi: 10.1126/science.abd3902. PubMed
717 PMID: 32764055.
- 718
- 719 45.Lalaoui R, Bakour S, Raoult D, Verger P, Sokhna C, Devaux C, et al. What could explain the late
720 emergence of COVID-19 in Africa? *New Microbes New Infect.* 2020;38:100760. Epub 2020/09/29. doi:
721 10.1016/j.nmni.2020.100760. PubMed PMID: 32983542; PubMed Central PMCID: PMCPMC7508045.
- 722
- 723 46.Ataide MA, Andrade WA, Zamboni DS, Wang D, Souza Mdo C, Franklin BS, et al. Malaria-induced
724 NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial
725 superinfection. *PLoS Pathog.* 2014;10(1):e1003885. Epub 2014/01/24. doi:
726 10.1371/journal.ppat.1003885. PubMed PMID: 24453977; PubMed Central PMCID: PMCPMC3894209.
- 727
- 728 47.McCall MB, Netea MG, Hermesen CC, Jansen T, Jacobs L, Golenbock D, et al. Plasmodium falciparum
729 infection causes proinflammatory priming of human TLR responses. *J Immunol.* 2007;179(1):162-71.
730 PubMed PMID: 17579034
731 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17579034)
732 [17579034](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17579034)[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&l](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=)
733 [ist_uids=](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=).
- 734
- 735 48.Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin
736 induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of
737 monocytes. *Proc Natl Acad Sci U S A.* 2012;109(43):17537-42. Epub 2012/09/19. doi:
738 10.1073/pnas.1202870109. PubMed PMID: 22988082; PubMed Central PMCID: PMCPMC3491454.

739

740

741

742

743 **Figure Legends**

744 **Figure 1. Monocytes of Malian adults exhibit reduced *P. falciparum*-inducible inflammatory**
745 **cytokine production and increased IL-10 production.** PBMCs were collected cross-sectionally
746 from an age-stratified cohort in Mali before the malaria season when all subjects were negative
747 for *Pf* infection by PCR; and also, from malaria-naïve U.S. adults. Monocytes were isolated from
748 thawed PBMCs and stimulated with iRBC lysate at a ratio of 1 monocyte to 30 iRBCs. After 24
749 hours, cell culture supernatants were analyzed to quantify secreted (A) TNF, (B) IL-1 β , (C) IL-6
750 and (D) IL-10. Means \pm SEM are shown. Data were analyzed by the Brown Forsythe and Welch
751 ANOVA test followed by Dunnett's T3 multiple comparison test. Level of significance between
752 groups are indicated by P values.

753

754 **Figure 2. Monocytes of Malian adults upregulate markers of M2 regulatory**
755 **monocytes/macrophages. (A-D)** Monocytes from Malian children (aged 4-6 years; n=9) and
756 adults (n=9) before the malaria season, as well as healthy malaria-naïve U.S. adults (n=7) were
757 analyzed *ex vivo* by flow cytometry for surface expression of CD14, CD16, CD163 and CD206. (A,
758 B) t-SNE analysis of monocytes for all subjects in each group. Expression of each marker is
759 indicated by a color scale. MFI of (C) CD163 and (D) CD206 surface expression on manually
760 gated live monocytes. (E,F) PBMCs were stimulated with *Pf*-iRBCs and analyzed for arginase-1

761 expression in monocytes intracellularly. **(E)** Representative t-SNE plots showing expression of
762 Arginase-1 in the clusters in three different groups of monocytes. Expression of Arginase-1 is
763 indicated by a color scale. **(F)**. Expression MFI level of intracellular Arginase-1 on manually
764 gated live monocytes comparing three different groups. Data were analyzed by the Mann-
765 Whitney test with Bonferroni adjustment, and the level of significance between groups is
766 indicated by P values.

767

768 **Figure 3. RNA-seq analysis of monocytes after *Pf*-iRBC stimulation reveals a regulatory**
769 **signature in Malian adults that is distinct from children.** Isolated monocytes from Malian
770 children (n=8) and adults (n=8) were stimulated *in vitro* with *Pf*-iRBC lysate at a monocyte: *Pf*-
771 iRBC ratio of 1:5 for 24 hours and then total RNA was isolated for sequencing. From separate
772 subjects (n=4 subjects in each age group), total RNA from unstimulated monocytes was also
773 sequenced. **(A)** Principal-component analysis of log₂-normalized gene counts across all
774 samples. **(B-E)** Heatmaps representing log₂-normalized gene counts of *Pf*-iRBC stimulated
775 monocytes from Malian children and adults. Each column represents one individual sample.
776 Heatmaps represent gene sets with pre-specified functions: **(4B)** M1/M2
777 monocyte/macrophage signature, **(4C)** inflammation, **(4D)** phagocytosis, and **(4E)** antigen
778 processing and presentation.

779

780 **Figure 4. In vitro model of monocyte to macrophage differentiation during exposure to *P.***
781 ***falciparum* blood-stage parasites.** Elutriated monocytes from healthy U.S. adults were
782 incubated for 24 hours with medium alone, uninfected red blood cells (RBC) or *Pf*-iRBC

783 (monocyte:*Pf*-iRBC ratio 1:15). At 24 hours, supernatants and cells were collected from some
784 replicate wells for cytokine analysis, and the ChIP assay, while monocytes in other replicate
785 wells were washed and incubated for 3 additional days in human serum plus medium to allow
786 monocytes to differentiate into macrophages (Mf). On day 5, the three populations of
787 macrophages (Mf, RBC-Mf and *Pf*-iRBC-Mf) were either harvested for ChIP and cytokine gene
788 expression analysis; or re-stimulated with *Pf*-iRBCs or LPS for 24 hours prior to supernatants
789 and cells being collected for cytokine analysis.

790

791 **Figure 5. Pre-exposure of monocytes to *P. falciparum* dampens subsequent inflammatory**
792 **responses to *P. falciparum* and LPS.** Monocytes of U.S. adults were incubated with medium,
793 RBC or *Pf*-iRBC. At 24 hours, cells were analyzed by (A) cytokine gene expression Taqman arrays
794 (n=3 subjects), and supernatants were analyzed by a bead-multiplexed assay (n=9 subjects) to
795 quantify (D) TNF, (E) IL-6 and (F) IL-1 β . In the same experiment, replicate monocytes were
796 incubated with medium, RBC or *Pf*-iRBC, washed at 24 hours and incubated for 3 additional
797 days in human serum to permit macrophage (Mf) differentiation. On day 5, the three
798 populations of macrophages were analyzed by (B) cytokine gene expression arrays (n=3
799 subjects). Finally, in the same experiment, replicate monocytes were incubated with medium,
800 RBC or *Pf*-iRBC, washed at 24 hours, incubated for 3 additional days in human serum to permit
801 Mf differentiation, and then co-cultured with *Pf*-iRBC or LPS for 24 hours. Cells were harvested
802 for (C) cytokine gene expression arrays (n=3 subjects), and supernatants were analyzed (n=9
803 subjects) to quantify TNF, IL-6 and IL-1 β induced by (G-I) *Pf*-iRBC or (L-N) LPS (n=14 subjects).
804 Δ Ct values (mean \pm SE) for (J) TNF and (K) IL-6 at the indicated timepoints for the 3 subjects

805 shown in A-C. (A-C) Heatmaps were generated from ΔCt values, with lower ΔCt values
806 corresponding to higher gene expression. ΔCt values were normalized to 18S rRNA expression.
807 (D-I and L-N) Lines represent median values. Data were analyzed by the Wilcoxon test with
808 Bonferroni adjustment, and significance levels between the groups are indicated by P values. (J
809 and K) Two-way ANOVA was performed followed by Tukey's multiple comparisons test.
810 Significance level between conditions (Pf-iRBC stim vs. Control Medium and Pf-iRBC stim vs.
811 RBC stim, respectively) are indicated by P values at each timepoint.

812

813 **Figure 6. *P. falciparum* exposure drives epigenetic reprogramming of monocyte/macrophages**
814 **toward a tolerant phenotype.** Monocytes of U.S. adults (n=4) were incubated with medium,
815 RBC or *Pf*-iRBC for 24 hours and then analyzed by chromatin immunoprecipitation (ChIP) and
816 RT-PCR to quantify H3K4me3 enrichment at (A) TNF and (D) IL-6 promoter sites. Replicate
817 monocytes were incubated with medium, RBC or *Pf*-iRBC, washed at 24 hours, and incubated
818 for 3 days in human serum to permit Mf differentiation. On day 5, cells were analyzed by ChIP
819 and RT-PCR to quantify H3K4me3 enrichment at (B) TNF and (E) IL-6 promoter sites. Finally,
820 replicate monocytes were incubated with medium, RBC or *Pf*-iRBC, washed at 24 hours,
821 incubated for 3 days in human serum, co-cultured with *Pf*-iRBC for 24 hours, and analyzed by
822 ChIP and RT-PCR to quantify H3K4me3 enrichment at (C) TNF and (F) IL-6 promoter sites.
823 Kinetics of H3K4me3 enrichment at (G) TNF and (H) IL-6 promoter sites across indicated
824 timepoints. Results are shown as means \pm SEM fold enrichment of H3K4me3 antibody as
825 percent of input. (A-F) One-way ANOVA with Tukey's adjustment for multiple comparisons. P
826 values indicate level of significance. (G, H) Two-way ANOVA with Tukey's adjustment for

827 multiple comparisons. P values indicate level of significance between Pf-iRBC vs. medium and
828 Pf-iRBC vs. RBC, respectively.

829

830 **Supplementary Table:** Table of differentially expressed genes of Pf-iRBC-stimulated PBMCs of
831 Malian adults versus children.

832 This table shows statistically significant ($p_{adj} < 0.01$) differentially expressed genes in monocytes
833 from Malian adults stimulated with Pf-iRBC relative to Pf-iRBC stimulated monocytes from
834 Malian children. Adjusted P values were calculated with the Benjamini-Hochberg method.

835

836 **Supplementary Figure 1.**

837 **Titration of monocyte: *Pf*-iRBC ratio for vitro model of monocyte to macrophage**
838 **differentiation.** Elutriated monocytes from healthy U.S. adults (n=3) were co-cultured with
839 increasing concentrations of *Pf*-iRBCs. After 24 hours, IL-1 β (A), TNF (B) and IL-6 (C) were
840 measured in supernatants, and (D) cell viability was determined by trypan blue dye exclusion
841 and expressed as percent viability.

842

843 **Supplementary Figure 2.**

844 **Cell viability at day 5 in the vitro model of monocyte to macrophage differentiation.**

845 Elutriated monocytes from healthy U.S. adults (n=9) were incubated for 24 hours with medium
846 alone, uninfected red blood cells (RBC) or *Pf*-iRBC (monocyte:*Pf*-iRBC ratio 1:15). At 24 hours,
847 cells were washed and incubated for 3 additional days in human serum plus medium to allow
848 monocytes to differentiate into macrophages (Mf). To quantify cell viability on day five, 10% v/v

849 alamarBlue HS was added to the culture medium of the three populations of macrophages (Mf,
850 RBC-Mf and *Pf*-iRBC-Mf) for 5 hours and fluorescence intensity (FI) was measured according to
851 the manufacturer's instructions. FI was normalized to the fluorescence signal in media without
852 cells. Data were analyzed by the Wilcoxon test with Bonferroni adjustment, and levels of
853 significance between the groups are indicated.

FIGURE-1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.10.21.346197>; this version posted November 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




FIGURE-2

bioRxiv preprint doi: <https://doi.org/10.1101/2020.10.21.346197>; this version posted November 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




FIGURE-3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.10.21.346197>; this version posted November 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.





FIGURE-4




FIGURE-5




FIGURE-6

